K3502
Anti-Human Kappa Light Chain (Bound and Free) antibody produced in goat
affinity isolated antibody, lyophilized powder
Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
About This Item
Productos recomendados
origen biológico
goat
Nivel de calidad
conjugado
unconjugated
forma del anticuerpo
affinity isolated antibody
tipo de anticuerpo
secondary antibodies
clon
polyclonal
formulario
lyophilized powder
técnicas
quantitative precipitin assay: suitable
temp. de almacenamiento
2-8°C
modificación del objetivo postraduccional
unmodified
Información sobre el gen
human ... IGK@(50802)
¿Está buscando productos similares? Visita Guía de comparación de productos
Descripción general
Anti-Human κ Light Chain (bound and free) antibody is obtained from goat antiserum. Immunospecific purification removes all goat serum proteins and immunoglobulins that do not bind to the κ light chain (bound and free). The antibody preparation is specific for κ light chains when tested against bound and free light chains. The product shows no reaction with bound or free λ light chains.
Inmunógeno
Purified human normal and myeloma κ light chain
Aplicación
Anti-Human κ Light Chain (Bound and Free)-FITC antibody was used for as secondary antibody in ELISA at a working antibody dilution of 1:200 using maize seed extracts. For ELISA using NSO/1 myeloma cells, HEK293 cells and mouse plasma, antibody concentration of 1-2 μg/ml was used. The antibody was also used to coat the electrode surface in the preparation of antiatrazine immunosensor.
Anti-Human Kappa Light Chain (Bound and Free) antibody produced in goat has been used in western blotting.
Forma física
Lyophilized from 0.01 M sodium phosphate, 0.015 M sodium chloride, pH 7.2
Reconstitución
Reconstitute with 0.135 M sodium chloride.
Cláusula de descargo de responsabilidad
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
¿No encuentra el producto adecuado?
Pruebe nuestro Herramienta de selección de productos.
Certificados de análisis (COA)
Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Los clientes también vieron
Characterization of immunological interactions at an immunoelectrode by scanning electron microscopy
Ambrosi A et al
Electroanalysis, 19, 244-252 (2007)
Yvonne J Rosenberg et al.
PloS one, 11(3), e0152760-e0152760 (2016-04-01)
Intravascular delivery of broadly neutralizing antibodies (bnAbs) has shown promise for prevention and treatment of HIV infection. However, multiple IV administrations in geographic locations with poor accessibility to medical care have practical limitations. We have assessed the efficacy of plant-derived
Yvonne Rosenberg et al.
PloS one, 8(3), e58724-e58724 (2013-03-28)
Passive immunotherapy using anti-HIV broadly neutralizing monoclonal antibodies (mAbs) has shown promise as an HIV treatment, reducing mother-to-child-transmission (MTCT) of simian/human immunodeficiency virus (SHIV) in non-human primates and decreasing viral rebound in patients who ceased receiving anti-viral drugs. In addition
Ruben J Boado et al.
Biotechnology and bioengineering, 96(2), 381-391 (2006-08-29)
A murine monoclonal antibody (MAb) to the human insulin receptor (HIR) has been engineered for use as a brain drug delivery system for transport across the human blood-brain barrier (BBB). The HIRMAb was humanized by complementarity determining region (CDR) grafting
S M Chamow et al.
Journal of immunology (Baltimore, Md. : 1950), 153(9), 4268-4280 (1994-11-01)
HIV infection depletes the immune system of the coordinating functions of CD4+ T cells and APCs, whereas the population of CD8+ CTLs remains largely intact: functional but undirected. We have developed a humanized bispecific immunoadhesin-antibody (BIA) that redirects these remaining
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
Póngase en contacto con el Servicio técnico